AriZona x Marvel Super LXR Hero Hydration - Acai Blueberry - 16oz (Pack of 12) – Low Sugar Sports Drink, Perfect for Athletes, Vitamins and Natural Flavors - Thirst Quencher

Product Information

Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986).

Shao, W. et al. Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF. Cancer Res. 78, 1537–1548 (2018). Terasaka, N. et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536, 6–11 (2003). Chen, J. D. & Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377, 454–457 (1995). Korach-Andre, M., Archer, A., Barros, R. P., Parini, P. & Gustafsson, J. A. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proc. Natl Acad. Sci. USA 108, 403–408 (2011). Horlein, A. J. et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377, 397–404 (1995).Lehmann, J. M. et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272, 3137–3140 (1997). Fu, X. et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276, 38378–38387 (2001). Lands, W. E. Metabolism of glycerolipids. 2. The enzymatic acylation of lysolecithin. J. Biol. Chem. 235, 2233–2237 (1960).

Levin, N. et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25, 135–142 (2005). Wang, L. et al. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc. Natl Acad. Sci. USA 99, 13878–13883 (2002). Svensson, S. et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 22, 4625–4633 (2003).Hetz, C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89–102 (2012). Stenson, B. M. et al. Activation of liver X receptor regulates substrate oxidation in white adipocytes. Endocrinology 150, 4104–4113 (2009).

Quinet, E. M. et al. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J. Lipid Res. 45, 1929–1942 (2004). Tabas, I., Garcia-Cardena, G. & Owens, G. K. Recent insights into the cellular biology of atherosclerosis. J. Cell Biol. 209, 13–22 (2015). Lands, W. E. & Merkl, I. Metabolism of glycerolipids. III. Reactivity of various acyl esters of coenzyme A with alpha’-acylglycerophosphorylcholine, and positional specificities in lecithin synthesis. J. Biol. Chem. 238, 898–904 (1963). a, Analysing potential liver damage in C57BL/6 wildtype mice upon a 3-week T0901317/sorafenib treatment. b, Liver-to-body ratio of mice upon a 3-week treatment with T0901317/sorafenib or carrier (values represent mean ± SD, n = 3 mice per group, statistical significance was calculated using two-tailed Student´s t test). c, Representative pictures of murine livers upon a 3-week treatment with T0901317/sorafenib or carrier that were stained with H+E, Oil red O, Ki67, cleaved caspase 3, TUNEL and Sirius red ( n = 3 mice per group). TUNEL and cleaved caspase 3 positive control = Intraperitoneal injection of Jo2 antibody. Sirius red positive control = Bi-weekly intraperitoneal injections of CCl 4 for 6 weeks. Ki67 positive control = Myc OE; Nras G12V HCC. Scale bars, 100 µm. d, Analysing potential liver damage in C57BL/6 wildtype mice upon 6 months of T0901317/sorafenib treatment. e, Liver-to-body ratio of mice upon a 6-month treatment with T0901317/sorafenib or carrier (values represent mean ± SD, n = 6 mice per group, statistical significance was calculated using two-tailed Student´s t test). f, Representative pictures of murine livers upon a 6-month treatment with T0901317/sorafenib or carrier that were stained with H + E, Oil red O, Ki67, cleaved caspase 3, TUNEL and Sirius red ( n = 6 mice per group). Scale bars, 100 µm. g,h, Weight development of mice during 2 weeks ( g) or 6 months ( h) of treatment with T0901317/sorafenib or carrier (values represent mean ± SD, n = 3 (g) or 6 (h) mice per group, statistical significance was calculated using two-tailed Student´s t test). Numerical source data are provided as source data files.Gibney, G. T. & Zager, J. S. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin. Drug Metab. Toxicol. 9, 893–899 (2013). Glass, C. K. & Saijo, K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 10, 365–376 (2010). Ito, A. et al. LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. eLife 4, e08009 (2015). Evans, R. M. & Mangelsdorf, D. J. Nuclear receptors, RXR, and the big bang. Cell 157, 255–266 (2014). US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00385489 (2009).